Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.43 |
| ▸ | RXRB | P28702 | 9/20 | 0.43 |
| ▸ | RXRG | P48443 | 6/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212489 | 0.97 | RXRA (0.43) | RXRARXRBRXRGLTB4RNR4A2 | |
| SCHEMBL5213384 | 0.93 | RXRA (0.47) | RXRARXRBRXRGNR4A2EGLN3 | |
| SCHEMBL5215187 | 0.87 | FAAH (0.42) | KMT2A | |
| SCHEMBL5206584 | 0.87 | KMT2A (0.41) | RXRARXRBRXRGKMT2AFGFR1 | |
| SCHEMBL5211701 | 0.86 | MKNK1 (0.42) | RXRARXRBRXRGNR4A2KMT2A | |
| SCHEMBL5216370 | 0.86 | HDAC6 (0.46) | RXRARXRBRXRGNR4A2EGLN3 | |
| SCHEMBL5215192 | 0.84 | PIN1 (0.43) | — | |
| SCHEMBL5211394 | 0.83 | HDAC6 (0.42) | RXRARXRBRXRGNR4A2EGLN3 | |
| SCHEMBL5211421 | 0.83 | TNKS (0.42) | KMT2A | |
| SCHEMBL5212347 | 0.83 | RXRA (0.39) | RXRARXRBRXRGLTB4RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | RXRA 1231/4885RXRB 1269/4885RXRG 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.